Exelixis | EXEL - Current Assets


Exelixis reported $1.21B in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.1B 33.9M Mar/2026
Agios Pharmaceuticals USD 717.67M 117.18M Jun/2026
Akebia Therapeutics USD 243.48M 9.47M Mar/2026
Amgen USD 31.48B 2.42B Mar/2026
AstraZeneca USD 27.97B 1.65B Jun/2026
Bayer EUR 35.3B 2.39B Mar/2026
BioMarin Pharmaceutical USD 4.61B 651.58M Mar/2026
Bristol-Myers Squibb USD 28.58B 1.37B Jun/2026
Cytokinetics USD 839.46M 77.51M Mar/2026
Eisai JPY 883.01B 121.38B Jun/2026
Eli Lilly USD 54.84B 794M Mar/2026
Exelixis USD 1.21B 234.65M Mar/2026
Genmab DKK 2.88B 1.59B Dec/2025
Glaxosmithkline GBP 17.76B 5.83B Mar/2026
Incyte USD 6.03B 542.31M Jun/2026
Ionis Pharmaceuticals USD 2.49B 446.73M Jun/2026
MacroGenics USD 182.52M 37.42M Mar/2026
Merck USD 35.02B 8.5B Mar/2026
Moderna USD 5.82B 45M Jun/2026
Nektar Therapeutics USD 589.04M 322.77M Mar/2026
Neurocrine Biosciences USD 1.64B 798.6M Jun/2026
Novartis USD 27.35B 744M Jun/2026
Pfizer USD 41.36B 1.46B Jun/2026
Puma Biotechnology USD 143.58M 7M Sep/2025
Sanofi EUR 30.16B 789M Mar/2026
Takeda JPY 3.15T 59.77B Jun/2026
Ultragenyx Pharmaceutical USD 657M 294M Mar/2026
Xencor USD 482.85M 116.97M Mar/2026